Unbuckling lipodystrophy from insulin resistance and hypertension.
Lipodystrophy and insulin resistance are the core features of human PPARgamma deficiency states. Metabolic complications in PPARgamma deficiency, such as hypertension, have been considered to be secondary to insulin resistance. However, a new mouse model that expresses the analog of a human PPARG mutation displays minimal lipodystrophy and insulin resistance but rather severe hypertension. Furthermore, the mutant protein appears to directly modulate the renin-angiotensin system in adipose tissue, providing evidence of the pleiotropic effects of PPARgamma.
Hegele
Robert A
RA
Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, 406-100 Perth Drive, London, Ontario N6A 5K8, Canada. hegele@robarts.ca
Leff
Todd
T
D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D006973:Hypertension / Q000378:metabolism*; D007333:Insulin Resistance / Q000502:physiology*; D008060:Lipodystrophy / Q000378:metabolism*; D051379:Mice; D018160:Receptors, Cytoplasmic and Nuclear / Q000172:deficiency / Q000235:genetics; D012084:Renin-Angiotensin System / Q000502:physiology; D014157:Transcription Factors / Q000172:deficiency / Q000235:genetics
D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors